Skip to main content
FASENRA 30 mg/mL injection, solution by AstraZeneca Pharmaceuticals LP
FASENRA, 30 mg/mL, injection, solution Drug class: Interleukin-5 Receptor alpha-directed Cytolytic Antibody. Available on prescription only. Listed by AstraZeneca Pharmaceuticals LP.
Prescription only

FASENRA

Benralizumab

Listed by AstraZeneca Pharmaceuticals LP

Strength
30 mg/mL
Form
Injection, Solution
Route
Subcutaneous
Class
Interleukin-5 Receptor alpha-directed Cytolyt…

What it contains

  • Benralizumab 30 mg/mL

FDA record

Dosage form Injection, Solution
Route Subcutaneous
Drug class Interleukin-5 Receptor alpha-directed Cytolytic Antibody
Approval route BLA — biologic licence
NDC code 0310-1830
FDA application BLA761070
RxNorm concept 1989104
Package sizes listed 2
Marketed since October 2019

Other products containing Benralizumab

See all

Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.

FASENRA

Benralizumab

Strength
30 mg/mL
Form
Injection, Solution
Class
Interleukin-5 Receptor alpha-directed C…
Rx only

AstraZeneca Pharmaceuticals LP

Not stocked by us — reference only

FASENRA

Benralizumab

Strength
10 mg/.5mL
Form
Injection, Solution
Class
Interleukin-5 Receptor alpha-directed C…
Rx only

AstraZeneca Pharmaceuticals LP

Not stocked by us — reference only

Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.